Burning Rock Biotech Ltd. posts Q3 revenue of RMB 131.6 million
Reuters
Nov 20
<a href="https://laohu8.com/S/BNR">Burning Rock Biotech</a> Ltd. posts Q3 revenue of RMB 131.6 million
Burning Rock Biotech Ltd. reported third quarter 2025 revenues of RMB 131.6 million, an increase of 2% year-over-year and a decrease of 11% sequentially. Central lab revenues were RMB 36.8 million, down 8% year-over-year and 10% quarter-over-quarter. Gross profit for the quarter was RMB 98.8 million, up 8% year-over-year. Net loss narrowed to RMB 16.8 million from RMB 35.7 million a year earlier, representing a 53% reduction. Adjusted EBITDA (Non-GAAP) was negative RMB 5.4 million, improving 67% year-over-year. The company achieved positive operating cash flow of RMB 16.4 million in the third quarter. Overseas revenues increased by 33% and pharma revenues rose by 72% for the first nine months of 2025 compared with the same period in 2024. Business developments included the use of the OncoCompass Focus ctDNA assay in the FAVOUR study and the submission and publication of the PROMISE study for a 9-cancer early detection test.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Burning Rock Biotech Ltd. published the original content used to generate this news brief on November 20, 2025, and is solely responsible for the information contained therein.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.